In a recent opinion piece in Helsingin Sanomat, Esa T. Männistö, an oncologist from Turku, stirred controversy by questioning the rationale behind administering costly cancer treatments to patients over the age of 80. He pointed out that such treatments may only extend life by a few months while potentially costing tens of thousands of euros, and in extreme cases, over €100,000. Männistö emphasized that the substantial annual expenditure on cancer treatment in Finland, estimated at €1.5 billion—nearly 40% attributed to drug therapies—could be better allocated towards elderly care and support services, which are critically underfunded and in high demand.